Skip to content

A Single Site Prospective, Non-randomized Study of Partial Breast Intracavitary Brachytherapy Devices to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01813825
Enrollment
300
Registered
2013-03-19
Start date
2004-11-30
Completion date
2015-12-31
Last updated
2013-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This Study Has Been Designed to Compile Information on the Efficacy of the Partial Breast Intracavitary Brachytherapy in the Post Market Setting.

Keywords

Mammosite

Brief summary

A registry is an observation database. Participation in this registry does not require any additional or different procedures or drugs other than those you would normally receive for breast cancer. Registry databases are used to identify trends in medical care that help the medical community identify optimal care for different diseases. The data will be compiled on the safety and performance of the Partial Breast Brachytherapy Applicator based on the information collected about the treatment and follow up visits.

Detailed description

PURPOSE OF STUDY The patient understand that she has cancer of the breast. The patient understand that is offered the opportunity to participate in a registry study to collect data on the FDA approved device,Partial Breast Brachytherapy Applicator. Partial Breast Brachytherapy is a treatment method that works by delivering radiation from inside the breast directly to the tissue where cancer is most likely to recur. The Partial Breast Brachytherapy Applicator is a device that has tiny catheters or wires that fit inside the lumpectomy cavity (the space left after the tumor is removed). Radioactive sources (seed) are placed within the device by a computer controlled machine. This radioactive source will deliver the radiation therapy to the breast A registry is an observation database. Participation in this registry does not require any additional or different procedures or drugs other than those you would normally receive for breast cancer. Registry databases are used to identify trends in medical care that help the medical community identify optimal care for different diseases. PROCEDURES If the patient agree to take part in this registry, data will be compiled on the safety and performance of the Partial Breast Brachytherapy Applicator based on the information collected about the treatment and follow up visits. POTENTIAL RISKS AND DISCOMFORTS There is no medical risk to the patient if she takes part in this registry, as she will continue to receive the same medical care as provided by her medical team. POTENTIAL BENEFITS: It is not possible to state that the patient will benefit from this study. The information obtained from study may be used scientifically and may possibly be helpful to others. ALTERNATIVES TO TREATMENT The patient participation is voluntary and she may choose not to participate in this study or she may stop at any time. The patient choice will not affect doctors from providing care. The patient will not lose any benefits if she choose not to participate or if you withdraw from this study. She is free to seek care from a doctor of her choice at any time.

Interventions

OTHERRegistry

Sponsors

St. Vincent's Medical Center
Lead SponsorUNKNOWN

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be 45 years of age or older * Be a Tis, T1, N0 M0 - American Joint Committee Classification * Have negative surgical margins (NSABP definition) after final surgery * Should have adequate skin spacing between balloon surface and surface of the skin (\>=7mm) * DCIS

Exclusion criteria

* Be pregnant or breast-feeding.(If appropriate, patient must use birth control during the study) * Have collagen-vascular disease * Have extensive intraductal component (Harvard Definition,\>25% DCIS) * Have infiltrating lobular histology

Design outcomes

Primary

MeasureTime frameDescription
A Single Site Prospective, Non Randomized Study of Partial Breast Intracavitary Brachytherapy Devices To Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities1-4 weeksThe efficacy of the treatment will be measured by using the overall survival. The following endpoints will also be reported and analyzed:Disease Free Survival, Cause Specific Survival, Ipsilateral Breast Failure, Contralateral Breast Failure.

Countries

United States

Contacts

Primary ContactDeborah Fang, MD
203-576-5085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026